advertisement
Abstract #24660 Published in IGR 11-4
Brinzolamide/timolol: In open-angle glaucoma and ocular hypertension
Croxtall JD; Scott LJDrugs and Aging 2009; 26: 437-446
(black up triangle) Brinzolamide 1timolol 0.5 fixed combination (brinzolamidetimolol) is a twice-daily eyedrops suspension comprising the carbonic anhydrase-II inhibitor brinzolamide and the (beta)-adrenergic receptor antagonist timolol. (black up triangle) Brinzolamidetimolol produced clinically relevant reductions in mean intraocular pressure (IOP) from baseline and was more effective than brinzolamide or timolol monotherapy in lowering IOP in a 6-month, randomized, phase III trial in patients with open-angle glaucoma or ocular hypertension (n523). The proportion of patients achieving a mean IOP of <18mmHg was significantly greater in recipients of brinzolamidetimolol than in recipients of brinzolamide or timolol monotherapy. (black up triangle) The IOP-lowering efficacy of brinzolamidetimolol was maintained for up to 12 months, and was no less effective than dorzolamide 2timolol 0.5 solution (dorzolamidetimolol) in a randomized, phase III, noninferiority trial (n437). (black up triangle) Brinzolamidetimolol was generally well tolerated and was associated with significantly lower ocular discomfort scores than dorzolamidetimolol. Moreover, a significantly greater number of patients expressed a preference for brinzolamidetimolol over dorzolamidetimolol. The main ocular adverse event was blurred vision, and was not considered to be a safety issue.
J. D. Croxtall. Wolters Kluwer Health/Adis, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz
Classification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
